Europe's pharma density fuels AI drug-discovery startups like Cradle
Proximity to global pharma giants (Novo Nordisk, Roche) in Europe gives AI application-layer companies immediate access to anchor customers, creating a defensible wedge for startups like Cr…
IVP concentrates AI capital on application layer with strong results
Liaw states most IVP AI investments are application-layer and expresses satisfaction; he sees Europe producing a scaling cohort of applied AI companies (e.g., Cradle in drug discovery) that…
Liaw notes at least three to four European neobanks are larger than the single US equivalent, driven by inherent cross-border payment pain points that US founders don't face, giving Europe…
European founders must target US expansion at $10-15M ARR, not $50M
Liaw observes the US-expansion threshold has dropped from ~$50M ARR to $10-15M; he advises sending a founding-team member to New York early to establish culture and hire US sales leadership…